Genmab — Share Issue/Capital Change 2015

Nov 11, 2015

Company Announcement

Copenhagen, Denmark; November 11, 2015 – Genmab A/S (OMX: GEN) will increase
its share capital by 209,133 shares as a consequence of the exercise of
employee warrants.

The increase is effected without any preemption rights for the existing
shareholders of the company or others. The shares are subscribed in cash at the
following price per share of nominally DKK 1:

-- 3,713 shares at DKK 31.75,
-- 50,000 shares at DKK 40.41,
-- 2,250 shares at DKK 55.85,
-- 1,000 shares at DKK 66.60,
-- 4,750 shares at DKK 67.50,
-- 250 shares at DKK 68.65,
-- 2,125 shares at DKK 79.25,
-- 500 shares at DKK 80.55,
-- 1,750 shares at DKK 129.75,
-- 5,000 shares at DKK 173,
-- 1,131 shares at DKK 184,
-- 5,000 shares at DKK 210.50,
-- 7,000 shares at DKK 220.40,
-- 812 shares at DKK 224,
-- 1,000 shares at DKK 225.30,
-- 1,000 shares at DKK 225.90,
-- 2,000 shares at DKK 231.50,
-- 500 shares at DKK 234,
-- 4,500 shares at DKK 234.75,
-- 3,400 shares at DKK 246,
-- 32,750 shares at DKK 254,
-- 12,625 shares at DKK 272,
-- 1,862 shares at DKK 326.50,
-- 3,900 shares at DKK 329,
-- 2,588 shares at DKK 330,
-- 44,815 shares at DKK 352.50, and
-- 12,912 shares at DKK 364.

Proceeds to the company are approximately DKK 44.9 million. The increase
corresponds to approx. 0.4 % of the company's share capital.

The increase includes the exercise of 50,000 warrants by President & CEO Jan
van de Winkel.

The new shares are ordinary shares without any special rights and are freely
transferable negotiable instruments. The new shares give rights to dividends
and other rights in relation to the company as of subscription, i.e. inter alia
full rights to dividends for the financial year 2015. The new shares will be
listed on Nasdaq Copenhagen after registration with the Danish Business
Authority. Genmab A/S' current share capital amounts to DKK 59,322,130 and will
after the capital increase be DKK 59,531,263. The capital increase is expected
to be finalized shortly.

About Genmab
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated antibody therapeutics for the
treatment of cancer. Founded in 1999, the company currently has one marketed
antibody, Arzerra® (ofatumumab) for the treatment of certain chronic
lymphocytic leukemia indications and daratumumab in clinical development for
multiple myeloma and non-Hodgkin’s lymphoma, in addition to other clinical
programs, and an innovative pre-clinical pipeline. Genmab's technology base
consists of validated and proprietary next generation antibody technologies -
the DuoBody® platform for generation of bispecific antibodies, and the
HexaBody® platform which creates effector function enhanced antibodies. The
company intends to leverage these technologies to create opportunities for full
or co-ownership of future products. Genmab has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™;
the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody®
and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates.

Company Announcement no. 54
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark